Skip to main content
Resverlogix Corp. logo

Resverlogix Corp. — Investor Relations & Filings

Ticker · RVX ISIN · CA76128M1086 LEI · 529900VI46SAPCOSH758 TSX Real estate activities
Open in API
Filings indexed 195 across all filing types
Latest filing 2023-03-03 Regulatory Filings
Country CA Canada
Listing TSX RVX

About Resverlogix Corp.

https://www.resverlogix.com/

Resverlogix Corp. is a late-stage clinical biotechnology company specializing in the development of epigenetic therapies for chronic illnesses. The company's core scientific focus involves regulating the expression of disease-causing genes. Its lead drug candidate is Apabetalone, a small molecule inhibitor currently being advanced through clinical programs, including the BETonMACE trial. Apabetalone is primarily targeted toward treating cardiovascular diseases and complications associated with diabetes mellitus. Resverlogix aims to provide novel science and value-based health solutions to key stakeholders, including pharmaceutical companies, physicians, and health payer groups.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the publication of scientific research articles related to the company's drug candidate apabetalone and its potential benefits in cardiovascular disease, heart failure, and COVID-19. It includes summaries of the research findings, mentions upcoming scientific conference participation, and provides background information about the company and the drug. There are no financial statements, regulatory filings, or detailed financial data presented. The document is not an earnings release, annual report, or any formal regulatory filing. It is a corporate announcement focused on research and development updates and scientific publications. Therefore, it best fits the category of a Regulatory Filing (RNS) as a general regulatory announcement and corporate update that does not fit into more specific categories.
2023-03-03 English
Report of exempt distribution excluding schedule 1 of Form 5.pdf
Regulatory Filings
2023-02-18 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled "Management’s Discussion & Analysis – Q3 2022" and references unaudited condensed interim consolidated financial statements for the three and nine months ended September 30, 2022. It contains detailed discussion of financial position, operational results, forward-looking statements, going concern considerations, and business overview. The length is about 15,000 characters, indicating a substantive report rather than a brief announcement. The content matches the typical Management Discussion and Analysis (MD&A) section that accompanies interim or quarterly financial reports. Therefore, the document is best classified as an Interim / Quarterly Report (IR).
2022-11-12 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F2 Certification of Interim Filings by the CFO of Resverlogix Corp. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended September 30, 2022. The document is primarily an officer certification letter confirming the accuracy and completeness of the interim filings, without containing the actual financial data or substantive financial analysis itself. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR) itself. The document length is 3372 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2022-11-12 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F2 Certification of Interim Filings by the President and CEO of Resverlogix Corp. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended September 30, 2022. The content is primarily an officer certification regarding the interim filings, controls, and procedures, without containing actual financial statements or substantive financial data. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself. The document length is 3394 characters, which is relatively short and consistent with a certification letter rather than a full interim report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-11-12 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document contains detailed unaudited condensed interim consolidated financial statements for the three and nine months ended September 30, 2022 and 2021. It includes comprehensive financial data such as statements of financial position, comprehensive loss, changes in shareholders' equity, cash flows, and extensive notes. The document references compliance with IAS 34 - Interim Financial Reporting, which governs interim reports. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is a full interim financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2022-11-11 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.